586 related articles for article (PubMed ID: 24568896)
1. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
[TBL] [Abstract][Full Text] [Related]
2. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
[TBL] [Abstract][Full Text] [Related]
3. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.
Lebdai S; Mathieu R; Leger J; Haillot O; Vincendeau S; Rioux-Leclercq N; Fournier G; Perrouin-Verbe MA; Doucet L; Azzouzi AR; Rigaud J; Renaudin K; Charles T; Bruyere F; Fromont G
Urol Oncol; 2018 Feb; 36(2):80.e17-80.e24. PubMed ID: 29153942
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of metabolic syndrome and prostate cancer.
Gacci M; Russo GI; De Nunzio C; Sebastianelli A; Salvi M; Vignozzi L; Tubaro A; Morgia G; Serni S
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):146-155. PubMed ID: 28220805
[TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
De Nunzio C; Simone G; Brassetti A; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
BMC Cancer; 2016 Jul; 16():407. PubMed ID: 27386844
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome diagnosis and widespread high grade prostatic intraepithelial neoplasia significantly increase prostate cancer risk: results from a multicenter biopsy study.
Cicione A; De Nunzio C; Tubaro A; Cantiello F; Manno S; Oliveira C; Lima E; Damiano R
BMC Cancer; 2016 Feb; 16():59. PubMed ID: 26846521
[TBL] [Abstract][Full Text] [Related]
7. Metabolic abnormalities linked to an increased cardiovascular risk are associated with high-grade prostate cancer: a single biopsy cohort analysis.
De Nunzio C; Truscelli G; Trucchi A; Petta S; Tubaro M; Gacci M; Gaudio C; Presicce F; Tubaro A
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):35-9. PubMed ID: 26439746
[TBL] [Abstract][Full Text] [Related]
8. Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.
Gómez-Gómez E; Carrasco-Valiente J; Campos-Hernández JP; Blanca-Pedregosa AM; Jiménez-Vacas JM; Ruiz-García J; Valero-Rosa J; Luque RM; Requena-Tapia MJ
J Cell Mol Med; 2019 Feb; 23(2):934-942. PubMed ID: 30450757
[TBL] [Abstract][Full Text] [Related]
9. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
[TBL] [Abstract][Full Text] [Related]
10. Patients with metabolic syndrome and widespread high grade prostatic intraepithelial neoplasia are at a higher risk factor of prostate cancer on re-biopsy: a prospective single cohort study.
Cicione A; Cantiello F; De Nunzio C; Tubaro A; Damiano R
Urol Oncol; 2014 Jan; 32(1):28.e27-31. PubMed ID: 23273912
[TBL] [Abstract][Full Text] [Related]
11. Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy.
Bhindi B; Xie WY; Kulkarni GS; Hamilton RJ; Nesbitt M; Finelli A; Zlotta AR; Evans A; van der Kwast TH; Alibhai SM; Trachtenberg J; Fleshner NE
Urology; 2016 Jul; 93():77-85. PubMed ID: 27015944
[TBL] [Abstract][Full Text] [Related]
12. Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study.
De Nunzio C; Brassetti A; Simone G; Lombardo R; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):438-445. PubMed ID: 29867154
[TBL] [Abstract][Full Text] [Related]
13. Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men.
Salgado-Montilla J; Soto Salgado M; Surillo Trautmann B; Sánchez-Ortiz R; Irizarry-Ramírez M
Lipids Health Dis; 2015 Sep; 14():111. PubMed ID: 26377420
[TBL] [Abstract][Full Text] [Related]
14. Association of metabolic syndrome with prostate cancer diagnosis and aggressiveness in patients undergoing transrectal prostate biopsy.
Fragkoulis C; Glykas I; Tzelves L; Stasinopoulos K; Lazarou L; Kaoukis A; Dellis A; Stathouros G; Papadopoulos G; Ntoumas K
Arch Ital Urol Androl; 2021 Sep; 93(3):291-295. PubMed ID: 34839634
[TBL] [Abstract][Full Text] [Related]
15. Midlife metabolic factors and prostate cancer risk in later life.
Dickerman BA; Torfadottir JE; Valdimarsdottir UA; Wilson KM; Steingrimsdottir L; Aspelund T; Batista JL; Fall K; Giovannucci E; Sigurdardottir LG; Tryggvadottir L; Gudnason V; Markt SC; Mucci LA
Int J Cancer; 2018 Mar; 142(6):1166-1173. PubMed ID: 29114858
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Syndrome is Associated with Prostate Cancer Diagnosed on Biopsy but not the Gleason Score and the Number of Cancer-Positive Cores: A Prospective Controlled Study.
Bayraktar Z; Şahin C; Yıldırım S; Karaca Y; Sinanoğlu O
Arch Esp Urol; 2023 Sep; 76(7):504-510. PubMed ID: 37867335
[TBL] [Abstract][Full Text] [Related]
17. The metabolic syndrome is associated with more aggressive prostate cancer.
Ozbek E; Otunctemur A; Dursun M; Sahin S; Besiroglu H; Koklu I; Erkoc M; Danis E; Bozkurt M
Asian Pac J Cancer Prev; 2014; 15(9):4029-32. PubMed ID: 24935591
[TBL] [Abstract][Full Text] [Related]
18. The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy.
Zhang GM; Zhu Y; Dong DH; Han CT; Gu CY; Gu WJ; Qin XJ; Sun LJ; Ye DW
Asian J Androl; 2015; 17(5):839-44. PubMed ID: 25652638
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.
Sourbeer KN; Howard LE; Andriole GL; Moreira DM; Castro-Santamaria R; Freedland SJ; Vidal AC
BJU Int; 2015 May; 115(5):736-43. PubMed ID: 24931061
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada.
Blanc-Lapierre A; Spence A; Karakiewicz PI; Aprikian A; Saad F; Parent MÉ
BMC Public Health; 2015 Sep; 15():913. PubMed ID: 26385727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
